2024年2月10日，FDA授予Humacyte血管创伤治疗优先审评资格，导致其股价上涨13%。 On Feb 10, 2024, the FDA granted Humacyte a priority review for its vascular trauma treatment, causing its shares to rise 13%.

2024 年 2 月 10 日星期六，美国食品和药物管理局 (FDA) 授予 Humacyte 正在开发的血管创伤治疗药物优先审查权。 On Saturday, 2024-02-10, the U.S. Food and Drug Administration (FDA) granted Humacyte a priority review for their vascular trauma treatment under development. 由于这一决定，Humacyte 的股价大幅上涨，周五上涨近 13% 至 3.53 美元。 As a result of this decision, Humacyte's shares saw a significant increase, rising by almost 13% to $3.53 on Friday. 这一增长标志着 Humacyte 的股价在过去 12 个月中增长了 21%。 This growth marks a 21% increase in Humacyte's shares over the last 12 months.

文章

MarketWatch

WKRB 13

Biztoc

-- 显示更少 --

延伸阅读

相关故事